New Zealand markets open in 6 hours 34 minutes

Clearmind Medicine Inc (CWY0.BE)

Berlin - Berlin Delayed price. Currency in EUR
Add to watchlist
0.9875+0.0015 (+0.15%)
As of 04:41PM CEST. Market open.
Full screen
Previous close0.9860
Open0.9360
Bid0.9275 x N/A
Ask1.0360 x N/A
Day's range0.9300 - 0.9875
52-week range0.8860 - 6.0000
Volume100
Avg. volume0
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink

    Vancouver, Canada, June 11, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announces advancement in its proprietary MEAI- based alcohol substitute beverage program. The Company previously announced the initiation of the last pre-clinical study required for a novel-food applicatio

  • GlobeNewswire

    Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product

    The global market of no- and low-alcohol beverages estimated at over $13 billion in 2023 Vancouver, Canada, May 10, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announces advancement in its proprietary MEAI- based alcohol substitute beverage program. The Company has completed m

  • GlobeNewswire

    Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment

    Vancouver, Canada, May 07, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announces the signing of an exclusive patent licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem. This agreement provides Clearmind with exclusive global right